Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Valneva ( (VALN) ) has shared an update.
Valneva SE announced positive Phase 2 trial results for its chikungunya vaccine, IXCHIQ®, in children, demonstrating a strong safety and immunogenicity profile. The trial results support the decision to use a full dose for the planned Phase 3 study in children aged one to eleven years, expected by the fourth quarter of 2025. This trial’s success is crucial for expanding the vaccine’s label to include children, especially in regions heavily affected by chikungunya. The vaccine, already approved for adults in several regions, addresses a significant unmet need for long-term protection against chikungunya in low- and middle-income countries.
More about Valneva
Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases that address unmet medical needs. The company leverages expertise across various vaccine modalities to provide first-, best-, or only-in-class vaccine solutions. Valneva markets three proprietary travel vaccines, including the world’s first chikungunya vaccine, and is advancing a pipeline that includes a Lyme disease vaccine candidate in partnership with Pfizer and other candidates against global health threats.
YTD Price Performance: -0.21%
Average Trading Volume: 41,554
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $378.6M
For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.
